Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma
Not Applicable
Recruiting
- Conditions
- Hepatocellular Carcinoma
- Registration Number
- NCT06694636
- Lead Sponsor
- Zhongda Hospital
- Brief Summary
Patients who met the inclusion criteria were treated with endovascular radiofrequency ablation and desympathetic nerve surgery. After enrollment, endovascular radiofrequency ablation and desympathetic surgery were performed. After radiofrequency ablation, the safety and efficacy of follow-up treatment will be carried out every 1 month or so, including blood routine, liver and kidney function, tumor indicators, abdominal CT/magnetic resonance, etc.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
- Clinically or pathologically confirmed hepatocellular carcinoma (HCC)
- Locally progressed or distant metastatic unresectable advanced HCC
- Progressed after second-line therapy
- Agree to participate in the study and sign the informed consent form
Exclusion Criteria
- Not suitable for ablation surgery
- Pregnant, lactating and planning to become pregnant
- Orthostatic hypotension
- Mixed liver cancer
- Intestinal obstruction
- Obvious bleeding tendencies and hematologic diseases
- Acute or severe systemic infection;
- Stroke or transient ischemic attack (TIA) within two weeks;
- Acute coronary syndrome within two weeks;
- Evaluated to be not suitable for this trial by investigators
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method ORR every month, up to 1 year Objective Response Rate
- Secondary Outcome Measures
Name Time Method PFS every month, up to 1 year Progression Free Survival
DCR every month, up to 1 year disease control rate
Trial Locations
- Locations (1)
Zhongda Hospital
🇨🇳Nanjing, Jiangsu, China